Skip to main content

Advertisement

SpringerLink
Log in

A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Uzoigwe CE (2015) The real enemy is fragility fracture, not osteoporosis. Osteoporos Int. doi:10.1007/s00198-015-3405-6

  2. Oden A, McCloskey EV, Johansson H, Kanis JA (2013) Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int 92(1):42–9

    Article  PubMed  CAS  Google Scholar 

  3. Jarvinen TL, Michaelsson K, Jokihaara J et al (2015) Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ 350:h2088

    Article  PubMed  Google Scholar 

  4. Ensrud KE, Black DM, Palermo L et al (1997) Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157(22):2617–24

    Article  PubMed  CAS  Google Scholar 

  5. Roux C, Reginster JY, Fechtenbaum J et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21(4):536–42

    Article  PubMed  CAS  Google Scholar 

  6. Kanis JA, Barton IP, Johnell O (2005) Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 16(5):475–82

    Article  PubMed  CAS  Google Scholar 

  7. McCloskey E, Selby P, Davies M et al (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19(5):728–36

    Article  PubMed  CAS  Google Scholar 

  8. Eastell R, Black DM, Boonen S et al (2009) Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 94(9):3215–25

    Article  PubMed  CAS  Google Scholar 

  9. McClung M, Boonen S, Torring O et al (2011) Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 27:211–218

    Article  Google Scholar 

  10. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077–82

    Article  PubMed  CAS  Google Scholar 

  11. McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22(1):135–41

    Article  PubMed  CAS  Google Scholar 

  12. McCloskey EV, Johansson H, Oden A et al (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27(7):1480–6

    Article  PubMed  CAS  Google Scholar 

  13. Cauley JA, Robbins J, Chen Z et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290(13):1729–38

    Article  PubMed  CAS  Google Scholar 

  14. Gnant M, Pfeifer G, Dubsky PC, et al (2015) Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. American Society of Clinical Oncology, J Clin Oncol 33, 2015 (suppl; abstr 504)

  15. Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 20(10):1675–82

    Article  PubMed  CAS  Google Scholar 

  16. Kanis JA, on behalf of the WHO Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. Sheffield: WHO Collaborating Centre, University of Sheffield, UK

  17. Johansson H, Oden A, Johnell O et al (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19(6):906–13

    Article  PubMed  Google Scholar 

  18. Leslie WD, Morin S, Lix LM et al (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23(1):75–85

    Article  PubMed  CAS  Google Scholar 

  19. Leslie WD, Majumdar SR, Lix LM et al (2012) High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 23(1):391–7

    Article  PubMed  CAS  Google Scholar 

  20. McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20(5):811–7

    Article  PubMed  CAS  Google Scholar 

  21. Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44(6):1049–54

    Article  PubMed  CAS  Google Scholar 

  22. Boonen S, Black DM, Colon-Emeric CS et al (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58(2):292–9

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Unit of Bone Metabolism, Department of Oncology and Metabolism Metabolic Bone Centre, Northern General Hospital, Herries Road, Sheffield, S5 7AU, UK

    E. McCloskey

Authors
  1. E. McCloskey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. McCloskey.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCloskey, E. A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base. Osteoporos Int 27, 417–419 (2016). https://doi.org/10.1007/s00198-015-3406-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-015-3406-5

Keywords

Search

Navigation